Strategic Partnerships Azurity is actively pursuing exclusive commercial partnerships in the US and Canada for D-PLEX100 with PolyPid, signaling openness to collaboration and co-market strategies that can expand distribution and access to new markets.

Growth Capital With recent investment from Audax Group and other investors to fuel next growth phase, there may be opportunities to align with Azurity on dedicated programs, capital-efficient launches, or strategic partnerships to accelerate sales in international or new therapeutic areas.

Global Footprint Azurity’s presence across more than 50 countries and a diversified portfolio spanning over 10 therapeutic areas provides multiple entry points for region-specific initiatives, licensing deals, or contract manufacturing and supply arrangements.

Manufacturing Focus Recent manufacturing facility closure and headcount reductions suggest a shift toward optimized production and potential opportunities to offer contract manufacturing, supply chain resilience services, or technology-enabled manufacturing improvements.

Technology Enablement Investments in modern promo review workflows and enterprise data tools (Palantir, Foundry, Oracle Cloud) indicate a data-driven sales and field enablement approach; this opens doors for analytics-enabled services, regulatory consulting, and AI-driven market access solutions.